Boule appoints David Metrena to lead US commercial organization

Boule has appointed David Metrena as SVP Commercial Operations US effective June 6. David will take over from Bob Ariano who will retire after more than 9 successful years with the organization.
“We are grateful to Bob Ariano for his strong contribution to the Boule US business, demonstrated by our market leading position in the 3-part segment in the US physician office lab market and wish him well for his new chapter in life. At the same time, I am really excited to welcome David to Boule to this very important leadership position. David has extensive experience in the diagnostic industries and has worked with both larger multinationals as well as smaller companies in different marketing, sales, and business development roles. An experienced leader with an excellent track record, I look very much forward to welcoming David to Boule,” says CEO and Group President, Jesper Söderqvist.

David brings over 25 years of experience in diagnostics, having held senior roles within organizations such as VistaLab Technologies, Bio-Chem Fluidics and Siemens Healthineers. From the bench to the C-Suite, David has first-hand knowledge in keeping the customer experience top of mind.

“I am grateful to be joining such an amazing team and humbled to follow in Bob’s footsteps. We have a bright future to look forward too, and the talent and future portfolio development to make it happen,” said David Metrena of his appointment.

For more information, please contact:
Jesper Söderqvist, CEO and Group President, Boule Diagnostics AB, phone +46 (0)70-689 05 90

About Boule Diagnostics AB (publ)
Boule Diagnostics AB is a global diagnostics company that develops, manufactures and markets instruments and consumable products for blood diagnostics. The company serves hospitals, clinics, laboratories and companies within blood diagnostics, in both human and veterinary hematology. The company operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through distributors, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011.


More News

Studies have shown complete blood count testing to be relevant for monitoring of severity and progression of Dengue fever

Discover the crucial role of gentle mixing in preventing pre-analytical errors in laboratory testing.